Monoclonal antibodies (mAbs) have become a critical component of cancer therapy, thanks to their precision in targeting tumor cells while preserving healthy cells. These biologics are known for their effectiveness and reduced side effects compared to traditional chemotherapy. Traditionally administered intravenously (IV) in clinical settings, mAbs require repeated treatments over time, which can
